Myeloproliferative Disorders Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)
Condition: Myeloproliferative Neoplasm Interventions: Drug: Fedratinib Oral Capsule 300 mg; Drug: Decitabine 20 mg/m2; Drug: Fedratinib Oral Capsule 400 mg Sponsors: Joseph Jurcic; Bristol-Myers Squibb Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2022 Category: Research Source Type: clinical trials
A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
Condition: Myeloproliferative Neoplasms Interventions: Biological: VAC85135; Drug: Ipilimumab Sponsors: Janssen Research & Development, LLC; Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 6, 2022 Category: Research Source Type: clinical trials
